An innovative non-invasive retinal biomarker for drug discovery leading to improved diagnostics and better treatments for Multiple Sclerosis patients

用于药物发现的创新非侵入性视网膜生物标志物，可改善多发性硬化症患者的诊断和更好的治疗

• 批准号: 10028366
• 金额: $ 30.38万
• 依托单位: NOVAI LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10028366
• 关键词: innovative; non; invasive; retinal; biomarker

Novai Ltd (Novai) is a UK biotech SME with a core project team of Dr John Maddison (Project Lead/CTO), Dr Jonathan Young (Data Scientist) and Professor Francesca Cordeiro (Scientific Lead). Novai is aiming to develop its retinal biomarker, DARC, for earlier disease detection so it can be used to identify and monitor progression in MS patients. This innovative biomarker will reduce R&D timelines and facilitate appropriate trial patient recruitment, leading to quicker and more accurate patient diagnostics and the introduction of better treatments sooner. It will replace current cumbersome and invasive biomarkers, improving the quality of life of MS patients and reducing morbidity/mortality. It has the potential to become a valuable companion of the UK government's Progressive Neurological Conditions Toolkit, which covers MS.

Novai Ltd（Novai）是一家英国生物技术中小企业，其核心项目团队包括John Maddison博士（项目负责人/CTO），Jonathan Young博士（数据科学家）和Francesca Cordeiro教授（科学负责人）。Novai的目标是开发其视网膜生物标志物DARC，用于早期疾病检测，以便用于识别和监测MS患者的进展。这种创新的生物标志物将缩短研发时间，促进适当的试验患者招募，从而更快、更准确地诊断患者，并更快地引入更好的治疗方法。它将取代目前繁琐和侵入性的生物标志物，提高MS患者的生活质量，降低发病率/死亡率。它有可能成为英国政府渐进性神经疾病工具包的宝贵伴侣，该工具包涵盖MS。